CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced AIM2-driven inflammasome activation in heart failure Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review

Clinical TrialVolume 73, Issue 1, January 2019

JOURNAL:J Am Coll Cardiol. Article Link

Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women

P Dewan, R Rørth, JJV McMurray et al. Keywords: HFrEF; gender; comorbidity; mortality; quality of life

FULL TEXT PDF